Altimmune, Inc.
NASDAQ: ALT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jerome Benedict Durso
- Employees
- 59
- Headquarters
- Gaithersburg, United States
- IPO year
- 2017
- Market cap
- $260.4M
- Website
- https://altimmune.com
Loading ALT…
Loading profile data…Frequently asked questions about ALT
What does Altimmune, Inc. (ALT) do?
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, explo...
Where does ALT trade?
Altimmune, Inc. (ALT) trades on the NASDAQ Global Market.
What sector is ALT in?
Altimmune, Inc. (ALT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Altimmune, Inc.?
Jerome Benedict Durso is the chief executive officer of Altimmune, Inc. (ALT).
Where is Altimmune, Inc. headquartered?
Altimmune, Inc. is headquartered in United States.
Does ALT pay a dividend?
Altimmune, Inc. (ALT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALT go public?
Altimmune, Inc. (ALT) completed its initial public offering in 2017.